Laboratorio de Neurociencias, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Mexico City 04530, Mexico.
Laboratorio de Medicina Traslacional Aplicada a Neurociencias, Enfermedades Crónicas y Emergentes, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.
Int J Mol Sci. 2023 Jun 15;24(12):10199. doi: 10.3390/ijms241210199.
Dopamine (DA) and dopamine agonists (DA-Ag) have shown antiangiogenic potential through the vascular endothelial growth factor (VEGF) pathway. They inhibit VEGF and VEGF receptor 2 (VEGFR 2) functions through the dopamine receptor D2 (D2R), preventing important angiogenesis-related processes such as proliferation, migration, and vascular permeability. However, few studies have demonstrated the antiangiogenic mechanism and efficacy of DA and DA-Ag in diseases such as cancer, endometriosis, and osteoarthritis (OA). Therefore, the objective of this review was to describe the mechanisms of the antiangiogenic action of the DA-D2R/VEGF-VEGFR 2 system and to compile related findings from experimental studies and clinical trials on cancer, endometriosis, and OA. Advanced searches were performed in PubMed, Web of Science, SciFinder, ProQuest, EBSCO, Scopus, Science Direct, Google Scholar, PubChem, NCBI Bookshelf, DrugBank, livertox, and Clinical Trials. Articles explaining the antiangiogenic effect of DA and DA-Ag in research articles, meta-analyses, books, reviews, databases, and clinical trials were considered. DA and DA-Ag have an antiangiogenic effect that could reinforce the treatment of diseases that do not yet have a fully curative treatment, such as cancer, endometriosis, and OA. In addition, DA and DA-Ag could present advantages over other angiogenic inhibitors, such as monoclonal antibodies.
多巴胺 (DA) 和多巴胺激动剂 (DA-Ag) 通过血管内皮生长因子 (VEGF) 途径显示出抗血管生成潜力。它们通过多巴胺受体 D2 (D2R) 抑制 VEGF 和 VEGF 受体 2 (VEGFR 2) 的功能，阻止重要的血管生成相关过程，如增殖、迁移和血管通透性。然而，很少有研究表明 DA 和 DA-Ag 在癌症、子宫内膜异位症和骨关节炎 (OA) 等疾病中的抗血管生成机制和疗效。因此，本综述的目的是描述 DA-D2R/VEGF-VEGFR 2 系统的抗血管生成作用机制，并汇编癌症、子宫内膜异位症和 OA 的实验研究和临床试验的相关发现。在 PubMed、Web of Science、SciFinder、ProQuest、EBSCO、Scopus、Science Direct、Google Scholar、PubChem、NCBI Bookshelf、DrugBank、livertox 和 ClinicalTrials 中进行了高级搜索。考虑了解释 DA 和 DA-Ag 在研究文章、荟萃分析、书籍、评论、数据库和临床试验中抗血管生成作用的文章。DA 和 DA-Ag 具有抗血管生成作用，可能加强对尚无完全治愈方法的疾病（如癌症、子宫内膜异位症和 OA）的治疗。此外，DA 和 DA-Ag 可能比其他血管生成抑制剂（如单克隆抗体）具有优势。
